Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncotarget. 2015 Nov 3;6(34):35589-601. doi: 10.18632/oncotarget.5853.

What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment.

Author information

  • 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
  • 2Department of Internal Medicine and Cardiovascular Disease, University of Palermo, Palermo, Italy.
  • 3DiBiMIS, Section of Gastroenterology, University of Palermo, Palermo, Italy.
  • 4Department of Radiology, University of Palermo, Palermo, Italy.
  • 5Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti, Italy.

Abstract

The RAS-related signalling cascade has a fundamental role in cell. It activates differentiation and survival. It is particularly important one of its molecules, B-RAF. B-RAF has been a central point for research, especially in melanoma. Indeed, it lacked effective therapeutic weapons since the early years of its study. Molecules targeting B-RAF have been developed. Nowadays, two classes of molecules are approved by FDA. Multi-target molecules, such as Sorafenib and Regorafenib, and selective molecules, such as Vemurafenib and Dabrafenib. Many other molecules are still under investigation. Most of them are studied in phase 1 trials. Clinical studies correlate B-RAF inhibitors and QT prolongation. Though this cardiovascular side effect is not common using these drugs, it must be noticed early and recognize its signals. Indeed, Oncologists and Cardiologists should work in cooperation to prevent lethal events, such as fatal arrhythmias or sudden cardiac death. These events could originate from an uncontrolled QT prolongation.

KEYWORDS:

B-RAF; B-RAF inhibitors; cardio-oncology; cardiotoxicity; dabrafenib

PMID:
26431495
PMCID:
PMC4742127
DOI:
10.18632/oncotarget.5853
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Impact Journals, LLC Icon for PubMed Central
    Loading ...
    Support Center